EMCURE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | EMCURE | Market Cap | 28,964 Cr. | Current Price | 1,532 ₹ | High / Low | 1,586 ₹ |
| Stock P/E | 43.6 | Book Value | 170 ₹ | Dividend Yield | 0.20 % | ROCE | 13.5 % |
| ROE | 11.6 % | Face Value | 10.0 ₹ | DMA 50 | 1,474 ₹ | DMA 200 | 1,400 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.74 % | PAT Qtr | 282 Cr. | PAT Prev Qtr | 118 Cr. |
| RSI | 56.1 | MACD | 8.34 | Volume | 1,32,657 | Avg Vol 1Wk | 2,23,836 |
| Low price | 889 ₹ | High price | 1,586 ₹ | PEG Ratio | -3.22 | Debt to equity | 0.50 |
| 52w Index | 92.3 % | Qtr Profit Var | 462 % | EPS | 33.7 ₹ | Industry PE | 27.6 |
📉 Chart & Trend: EMCURE is trading at ₹1,532, above both its 50 DMA (₹1,474) and 200 DMA (₹1,400). This indicates strong short-term and medium-term support. The stock is in a trending uptrend with momentum strength.
📊 Momentum Indicators:
- RSI at 56.1 shows healthy momentum, not overbought yet.
- MACD at 8.34 confirms bullish crossover.
- Bollinger Bands: Price is near the upper band, suggesting strong buying interest but caution for short-term pullback.
- Volume is below average (1,32,657 vs 2,23,836), indicating reduced participation despite bullish signals.
📈 Support & Resistance:
- Immediate support: ₹1,474 (50 DMA).
- Strong support: ₹1,400 (200 DMA).
- Resistance zones: ₹1,586 (recent high).
- Optimal entry: ₹1,480–1,500 near support.
- Exit zone: ₹1,570–1,590 if momentum sustains.
🔎 Trend Status: The stock is trending upward, supported by bullish indicators and strong fundamentals.
Positive
- Strong ROCE (13.5%) and ROE (11.6%) show improving capital efficiency.
- PAT surged to ₹282 Cr from ₹118 Cr, reflecting robust growth.
- EPS of ₹33.7 indicates solid earnings power.
- FII (+0.30%) and DII (+1.74%) holdings increased, showing institutional confidence.
Limitation
- High P/E of 43.6 compared to industry PE of 27.6 suggests premium valuation.
- PEG ratio of -3.22 indicates valuation concerns relative to growth expectations.
- Debt-to-equity ratio at 0.50 is higher than peers, adding leverage risk.
Company Negative News
- Premium valuation may limit upside in the near term.
- Debt levels are higher compared to low-leverage peers in pharma sector.
Company Positive News
- Quarterly profit growth of 462% highlights strong operational turnaround.
- Institutional investors (FII & DII) increased stake, reflecting confidence in growth trajectory.
Industry
- Pharmaceutical sector remains defensive with steady demand and global growth opportunities.
- Industry PE at 27.6 is lower than EMCURE’s PE, suggesting premium valuation for brand strength and growth potential.
Conclusion
📌 EMCURE is trending upward, supported by bullish technical signals and strong fundamentals. Entry is favorable around ₹1,480–1,500 with stop-loss below ₹1,450. Short-term upside targets lie at ₹1,570–1,590. While valuations are premium, strong earnings growth and institutional support make it attractive for momentum and long-term investors.
Would you like me to extend this into a peer benchmarking overlay against pharma leaders like Cipla, Sun Pharma, and Dr. Reddy’s to highlight relative strength and sector rotation opportunities?